Corporate News: Dimerix Limited (DXB.AX)
Dimerix Limited (DXB.AX) closed the trading session on Wednesday 21 September 2026 at AUD 0.20, reflecting a decline of 4.55 % from the previous day’s close. At 12:54 AM Central European Time, the share price had settled below the 200‑day simple moving average, which is currently positioned at AUD 0.31. This drop follows a broader trend of a 10.64 % decline since the end of the previous month.
Trading Statistics
- Current price: AUD 0.20
- Shares outstanding: 629 million
- Market capitalization: AUD 132.1 million
- Volume in the last 24 hours: approximately AUD 145.4 k
- 52‑week high: AUD 0.66 (23 December 2025)
- 52‑week low: AUD 0.16 (11 June 2026)
The recent decline places the stock roughly 19 % below its year‑high while remaining only 26 % above its year‑low, signalling a moderate contraction in investor confidence.
Peer Performance
In the same 24‑hour period, the following Australian-listed companies displayed varied performance:
| Company | Ticker | % Change | Current Price (AUD) | Market Capitalisation (AUD mn) |
|---|---|---|---|---|
| West Wits Mining | WWI.AX | +1.43 % | 0.34 | 152.2 |
| Fortifai | FTI.AX | –1.1 % | 0.41 | 157.6 |
| Betr Entertainment | BBT.AX | 0 % | 0.15 | 157.0 |
| Stakk | SKK.AX | –20.83 % | 0.02 | 153.1 |
| Vita Life Sciences | VLS.AX | –4.15 % | 2.79 | 156.3 |
Vita Life Sciences, while trading lower than its peers, maintains a price‑to‑earnings ratio of 14.22, suggesting a relatively balanced valuation relative to its earnings potential.
Company Overview
Dimerix Limited is a biotechnology firm headquartered in Fitzroy, Australia. The company focuses on the development and marketing of pharmaceutical therapies targeted at patients with chronic kidney disease. In addition to its drug pipeline, Dimerix conducts clinical trials to evaluate new treatments for this patient population. Operations are confined to the Australian market, and the company maintains a presence on the ASX All Markets platform. Further details are available on the company’s website at www.dimerix.com .
This article provides a concise snapshot of Dimerix Limited’s recent market performance and contextualizes its position relative to select peers within the Australian equities market.
